More than 11,000 bottles of the blood‑pressure medication chlorthalidone (USP, 25 mg) are being recalled nationwide after the Food and Drug Administration identified a failure to meet dissolution specifications.
Dissolution testing evaluates how quickly a drug releases its active ingredient when introduced to a liquid, a key quality measure for pharmaceutical products.
The recall involves tablets manufactured by Inventia Healthcare Limited in India, which voluntarily initiated the action, and distributed in the United States by Rising Pharma Holdings of East Brunswick, New Jersey.
The FDA’s recall notice indicates that the affected bottles contain either 100 or 1,000 tablets, each labeled with batch codes RISA24001 (100‑tablet bottles) or RISB24002 (1,000‑tablet bottles). All recalled units bear an expiration date of April 2027.
Chlorthalidone is a diuretic used to treat high blood pressure by helping the kidneys eliminate excess fluid and salt. It is also prescribed to reduce swelling associated with heart, kidney, or liver conditions.
Fox Business has contacted Inventia Healthcare and Rising Pharma for comment.